Lansoprazole Accord Healthcare Ireland

Lansoprazole, the active ingredient in Lansoprazole Accord Healthcare Ireland, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is prescribed for acid‑related disorders such as gastro‑oesophageal reflux disease and ulcers. GNH USA supplies Lansoprazole Accord Healthcare Ireland as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage conditions associated with excess gastric acid. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by lowering stomach acidity. - Erosive esophagitis: promotes healing of acid‑damaged esophageal lining. - Duodenal ulcer: supports ulcer resolution through acid suppression. - Helicobacter pylori eradication (in combination therapy): enhances antibiotic effectiveness by creating a less acidic environment. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid in this rare endocrine disorder.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Diarrhea: loose stools that may resolve with continued use. - Nausea: feeling of queasiness without vomiting. - Abdominal pain: discomfort or cramps in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: rare skin blistering disorders. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Interstitial nephritis: inflammation of kidney tissue. - Long‑term fracture risk: reduced bone mineral density with prolonged use.

Before initiating therapy, consider the following precautions: - Assess renal function: adjust use in patients with severe kidney impairment. - Monitor for infections: be vigilant for signs of C. difficile or other gastrointestinal infections. - Evaluate need for long‑term therapy: limit duration when possible to reduce adverse risk. - Use caution in pregnancy: weigh potential benefits against unknown fetal risks. - Review concomitant medications: consider possible drug‑drug interactions. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lansoprazole may interact with several medicines, requiring attention to the level of interaction. Major Interactions (Avoid): - Ketoconazole: reduced absorption due to increased gastric pH. - Atazanavir: decreased antiviral efficacy. - Clopidogrel: diminished antiplatelet activation. - Warfarin: potential increase in INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Digoxin: possible increase in serum levels. - Phenytoin: altered metabolism may affect seizure control. - Rifampin: may reduce lansoprazole effectiveness. - Theophylline: increased plasma concentrations. - Methotrexate: enhanced toxicity with high‑dose regimens.